Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

If you have a certain type of arthritis or disease that causes inflammation, your doctor may recommend Remicade. It’s a prescription drug used in certain situations to treat: Remicade contains the ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Drug clearance was associated with a reduction in disease activity in children who responded to ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

Birmingham, UK - Although infliximab (Remicade, Centocor) was licensed for use in the treatment of ankylosing spondylitis (AS) in Europe nearly 2 years ago, in the UK there has been little experience ...

A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...

crohns disease Patients with Crohn disease were enrolled in a comparative cohort study that analyzed the outcomes of reference product infliximab vs biosimilar treatment. The effectiveness of ...

An open-label randomized trial compared combination therapy for Crohn’s disease with conventional therapy in 133 newly diagnosed patients (mean duration of diagnosis two weeks) (Lancet.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. launch of RENFLEXIS™ (infliximab-abda), a biosimilar of the originator ...